豪门国际
中文
EN
HOME
ABOUT US
Company Profile
Core Team
Mission Vision
Thesis
Patent
Partner
PHARMACODYNAMIC
Ferroptosis
Immunosuppression
Photo Thermal Photochemical Effect
CLINICAL APPLICATION
Pancreatic cancer
Undifferentiated thyroid carcinoma
Soft tissue sarcoma
Small Cell Lung Cancer
Colorectal Cancer
Breast cancer
Malignant Melanoma
CLINICAL TRIALS
PHASE I CLINICAL TRIAL RESULTS
IbIIa PHASE CLINICAL TRIAL
SARCOMA PROGRESSION
PRODUCTS
Products
Cooperation and Introduction of Products
NEWS
Company News
Industry News
Media Coverage
Announcement
PATIENT RECRUITMENT
CONTRACT
豪门国际产品
PRODUCTS
Products
Cooperation and Introduction of Products
其他管线项目
依托自主搭建的全球领先铁死亡多组学分析平台与高通量药物筛选系统,我司聚焦GPX4、DHODH、FSP1等铁死亡核心靶点,构建了"激动剂-抑制剂"双轨联动的创新药物开发策略。通过整合商业化合物库深度筛选、人工智能辅助结构优化及新型纳米递送技术,我们已成功开发出具有全球竞争力的肿瘤选择性铁死亡诱导疗法。
分享到:
上一条
免疫佐剂
Cooperation and Introduction of Products
上一条
没有了
ABOUT US
Company Profile
Core Team
Mission Vision
Thesis
Patent
Partner
PHARMACODYNAMIC
Ferroptosis
Immunosuppression
Photo Thermal Photochemical Effect
CLINICAL APPLICATION
Pancreatic cancer
Undifferentiated thyroid carcinoma
Soft tissue sarcoma
Small Cell Lung Cancer
Colorectal Cancer
Breast cancer
Malignant Melanoma
CLINICAL TRIALS
PHASE I CLINICAL TRIAL RESULTS
IbIIa PHASE CLINICAL TRIAL
SARCOMA PROGRESSION
PRODUCTS
Products
Cooperation and Introduction of Products
NEWS
Company News
Industry News
Media Coverage
Announcement
PATIENT RECRUITMENT
CONTRACT
豪门国际医药官方微信平台
Copyright © njborn.com All Rights Reserved. 四川豪门国际医药科技有限公司 版权所有
蜀ICP备2024061345号
网站建设:
XML地图